Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

Video

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

It is important to distinguish whether CAR T-cell therapy is a technology that will work against a specific antigen, or if there are other antigens that can be targeted in other tumors. Both CD19 and BCMA have proven to be targets in hematologic malignancies for CAR T-cell therapy. In solid tumors, it has been more difficult to find an application for CAR T-cell therapy, Brentjens explains.

The idea of moving CAR T-cell therapy to solid tumors has a number of immunological issues, Brentjens says. First, target antigens in solid tumors are not as ideal as CD19 or BCMA. Second, antigens are not as universally expressed by all solid tumor cells. Third, solid tumors tend to scaffold themselves with immune inhibitory elements such as regulatory T cells, myeloid-derived suppressor cells, and inhibitory ligands such as PD-L1. It is going to be more challenging to get CAR T-cell therapy to work in solid tumors, but it is not impossible, Brentjens says.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.